Feline Infectious Upper Respiratory Disease Complex (URI)

Feline Infectious Upper Respiratory Disease Complex (URI), colloquially known as "cat flu," is a highly contagious syndrome of the upper respiratory tract affecting domestic and wild felids worldwide. The condition is most commonly caused by a combination of viral and bacterial pathogens that produce overlapping clinical signs involving the nasal passages, pharynx, larynx, and ocular tissues. It represents one of the most frequently encountered infectious conditions in veterinary practice, particularly in multi-cat environments such as shelters, catteries, and feral cat colonies. While most healthy adult cats recover with appropriate supportive care, URI can be life-threatening in neonates, geriatric individuals, and immunocompromised cats.

Primary Viral Pathogens:

Feline Herpesvirus-1 (FHV-1 / Feline Rhinotracheitis Virus) accounts for approximately 40–45% of URI cases. It is an enveloped double-stranded DNA virus of the family Herpesviridae. After initial infection via direct contact with infected secretions, FHV-1 replicates in the epithelium of the nasal turbinates, pharynx, conjunctiva, and tonsils, causing necrosis and intense inflammatory responses. A hallmark feature is the establishment of lifelong latency in the trigeminal ganglia. Reactivation — triggered by stress, corticosteroid administration, lactation, or concurrent illness — leads to recurrent bouts of clinical disease and intermittent viral shedding, making latently infected cats a persistent reservoir.

Feline Calicivirus (FCV) is responsible for approximately 40–50% of URI cases. It is a non-enveloped single-stranded RNA virus of the family Caliciviridae with high genetic variability due to its error-prone RNA polymerase. FCV infects the oral mucosa and respiratory epithelium, producing characteristic vesicular lesions that rupture into ulcers. Its RNA genome mutates rapidly, allowing immune evasion and the emergence of antigenically distinct strains. Certain highly virulent strains (VS-FCV) can cause systemic endothelial damage, multi-organ failure, and significant mortality.

Secondary and Contributing Bacterial Pathogens:

• ·Bordetella bronchiseptica: A primary respiratory pathogen in its own right, it adheres to respiratory cilia and produces toxins that impair mucociliary clearance, predisposing to secondary pneumonia.
• ·Chlamydia felis (formerly Chlamydophila felis): An obligate intracellular bacterium that is a primary cause of persistent, predominantly ocular disease (follicular conjunctivitis); respiratory signs are mild and secondary.
• ·Mycoplasma felis: Commonly isolated as a secondary pathogen, contributing to conjunctivitis and lower respiratory signs.

Pathophysiological Cascade:

Initial viral replication destroys the mucociliary epithelium, impairing the first line of respiratory defense. This leads to mucosal edema, excessive secretion production, and nasal obstruction. Loss of olfaction combined with fever results in anorexia. Epithelial barrier disruption enables secondary bacterial colonization, transforming serous nasal discharge into purulent exudate and potentially extending infection to the sinuses, middle ear, or lower airways. In neonates and immunocompromised animals, overwhelming systemic involvement can occur.

Transmission:

The complex spreads primarily through direct contact with ocular, nasal, and oral secretions from infected or carrier cats. Fomite transmission (shared food bowls, bedding, hands of handlers) is significant, especially for FCV, which can survive in the environment for days to weeks. Aerosol transmission over short distances is also documented.

Clinical Diagnosis:

A presumptive diagnosis is typically made on the basis of history and clinical signs, particularly in cats from multi-cat environments, shelters, or recently adopted animals. The constellation of sneezing, nasal and ocular discharge, and oral ulceration is highly suggestive.

Physical Examination Findings:

• ·Detailed oral examination for vesicles and ulcers (classic for FCV)
• ·Ocular examination including fluorescein staining to identify dendritic or geographic corneal ulcers (highly suggestive of FHV-1)
• ·Palpation of submandibular lymph nodes for enlargement
• ·Thoracic auscultation to assess for secondary pneumonia

Laboratory Diagnostics:

Complete Blood Count (CBC):

• ·WBC (White Blood Cell Count): May be elevated in cases with significant secondary bacterial infection (neutrophilia with or without a left shift); a leukopenia (low WBC) can occur acutely during active viral replication, particularly with FHV-1.
• ·HCT (Hematocrit/PCV): May be mildly decreased in chronically ill, anorexic cats reflecting anemia of chronic disease; significantly low in severe VS-FCV cases with hemorrhage.
• ·PLT (Platelets): May be decreased (thrombocytopenia) in severe systemic FCV infection due to consumptive coagulopathy.

Serum Biochemistry:

• ·ALB (Albumin): May be low (hypoalbuminemia) in severely ill, anorexic, or systemically affected cats with protein loss.
• ·GLOB (Globulins): May be elevated with chronic infection and immune stimulation.
• ·ALT (Alanine Aminotransferase): May be mildly elevated in severe systemic FCV (VS-FCV) due to hepatic involvement; also elevated secondary to hepatic lipidosis from prolonged anorexia.
• ·TBIL (Total Bilirubin): May be elevated in VS-FCV with concurrent liver involvement or hemolysis.
• ·BUN / CREA: Generally within normal limits unless concurrent renal disease or severe dehydration is present.

Specific Diagnostic Testing:

• ·PCR (Polymerase Chain Reaction): The gold standard for identifying specific pathogens (FHV-1, FCV, Chlamydia felis, Bordetella bronchiseptica, Mycoplasma). Samples are collected via conjunctival or oropharyngeal swabs. PCR is sensitive but must be interpreted with caution, as latently infected cats may shed FHV-1 intermittently, and vaccine strains of FCV can yield positive results.
• ·Viral isolation: More technically demanding; primarily used in research or outbreak investigation.
• ·Immunofluorescence antibody (IFA) testing: Can detect FHV-1 and FCV antigen in cytological preparations; less sensitive than PCR.
• ·Serology: Antibody titers are of limited clinical utility in diagnosing active infection due to widespread vaccination and high prevalence of natural exposure; more useful for population-level seroprevalence studies.
• ·Cytology: Conjunctival scrapings may reveal intracytoplasmic inclusions with Chlamydia felis infection.

Imaging:

• ·Thoracic radiographs are indicated when lower respiratory involvement is suspected; interstitial to alveolar patterns may indicate secondary pneumonia.
• ·Skull radiographs or CT imaging can delineate sinus involvement in cats with chronic rhinosinusitis secondary to FHV-1.

Supportive Care (Cornerstone of Management):

• ·Nutritional support: Maintaining caloric intake is critical. Warming food, offering aromatic foods, or syringe feeding may be necessary. Esophagostomy or nasogastric tube placement is indicated for cats that are anorexic for more than 3–5 days. Prevention of hepatic lipidosis is a priority.
• ·Fluid therapy: Intravenous or subcutaneous fluids to correct dehydration and maintain hydration, particularly important in febrile, anorexic cats.
• ·Nasal hygiene: Gentle cleaning of dried nasal and ocular discharge with warm, moist cloths; nebulization with saline to loosen secretions; placement in a steam-humidified environment may relieve congestion.
• ·Mucolytics: N-acetylcysteine (oral or nebulized) may be used adjunctively to help liquefy thick secretions.
• ·Nasal decongestants: Pediatric topical saline or very dilute oxymetazoline drops (used judiciously and short-term) can provide relief from nasal obstruction.

Antiviral Therapy (FHV-1):

• ·Famciclovir (oral prodrug of penciclovir): Currently the antiviral of choice for FHV-1 in cats; typical dosing 40–90 mg/kg PO every 8–12 hours. It significantly reduces viral replication and severity of ocular and nasal disease.
• ·Lysine supplementation (L-lysine): Historically recommended as an arginine antagonist to inhibit FHV-1 replication; however, recent evidence has questioned its efficacy, and some current guidelines no longer recommend it.
• ·Topical antiviral ophthalmic medications: Trifluridine (1%) or idoxuridine (0.1%) ophthalmic solutions applied to corneal ulcers every 4–6 hours; ganciclovir ophthalmic gel is also used. These are essential for managing FHV-1 corneal disease.
• ·Cidofovir (0.5% topical ophthalmic): Twice-daily application shown to be effective against FHV-1 ocular disease with the advantage of less frequent dosing.

Antimicrobial Therapy:

• ·Antibiotics are indicated for documented or strongly suspected secondary bacterial infections, not for uncomplicated viral URI.
• ·Doxycycline (5–10 mg/kg PO once daily or divided BID): First-line choice; active against Chlamydia felis, Mycoplasma, and many secondary bacterial pathogens. Must be administered with food and water to avoid esophageal stricture.
• ·Azithromycin (5–10 mg/kg PO once daily): A practical alternative, particularly for Chlamydia felis and Mycoplasma.
• ·Amoxicillin-clavulanate: Useful for secondary bacterial infections when Gram-positive or mixed bacteria are suspected.
• ·Fluoroquinolones (e.g., marbofloxacin, pradofloxacin): Reserved for refractory or severe bacterial infections; use with caution and avoid high doses in young growing cats.

Ocular Management:

• ·Topical antibiotic ophthalmic preparations (e.g., tetracycline, fusidic acid, chloramphenicol ointment) for bacterial conjunctivitis and secondary ocular infections.
• ·Corneal ulcers warrant aggressive antiviral and antibiotic topical treatment; referral to a veterinary ophthalmologist should be considered for severe or non-healing ulcers.
• ·Symblepharon (adhesion of conjunctiva to cornea) is a sequel of severe FHV-1 ocular disease, particularly in kittens; surgical correction may eventually be needed.

Management of VS-FCV:

Virulent systemic FCV requires intensive hospitalization, aggressive fluid therapy with colloid support, broad-spectrum antibiotics, and potentially antiviral therapy. Given its contagiousness and high mortality, strict isolation and contact precautions are essential. Standard FCV vaccines may provide limited cross-protection against highly divergent VS-FCV strains.

Corticosteroids: Generally contraindicated or used with extreme caution in acute URI, as they can reactivate latent FHV-1 and exacerbate viral infections. They may be considered at low doses for specific complications (e.g., refractory symblepharon) under specialist guidance.

Interferon Therapy:

• ·Feline interferon-omega (Virbagen Omega; available in Europe and Japan): May modulate immune response and reduce clinical severity.
• ·Human recombinant interferon-alpha (low-dose oral): Used empirically in some practices.

Overall Prognosis:

The prognosis for uncomplicated URI in otherwise healthy adult cats is generally good, with most cats recovering within 1–3 weeks with appropriate supportive care. However, several factors significantly influence outcome.

Factors Associated with Worse Prognosis:

• ·Age: Neonates and kittens under 8–12 weeks of age carry a guarded to poor prognosis, particularly with FHV-1 pneumonitis or overwhelming systemic disease. Mortality in neonatal litters can approach 50% or higher without aggressive intervention.
• ·Immune status: Concurrent FIV or FeLV infection, severe malnutrition, or immunosuppressive therapy dramatically worsens prognosis.
• ·Pathogen involved: VS-FCV (Virulent Systemic FCV) carries a reported mortality rate of 40–67% in affected cats during outbreaks, making it the most severe manifestation within the complex.
• ·Shelter vs. owned cats: Shelter cats with poor nutritional condition, high stress, and concurrent disease have higher morbidity and mortality rates than well-managed pet cats.
• ·Chronicity: Cats that develop chronic rhinosinusitis secondary to FHV-1-induced turbinate destruction may require lifelong management; while not typically fatal, quality of life can be significantly affected.

Long-Term Considerations:

• ·FHV-1 latency means approximately 45–80% of infected cats become lifelong carriers and may experience recurrent episodes of clinical disease under periods of physiological stress.
• ·FCV-carrier cats (continuous active shedding from tonsils) may shed virus for months to years, and the carrier state does not resolve as predictably as with FHV-1.
• ·Chronic sequelae include persistent rhinitis, nasal turbinate destruction, symblepharon, corneal scarring, and in some cases, chronic stomatitis (particularly associated with FCV).
• ·Cats with severe corneal ulceration risking perforation carry a guarded to poor prognosis for vision in the affected eye.

Mortality in Shelter Populations:

URI is a leading cause of euthanasia decisions in animal shelters due to resource limitations and risk to other cats, though medical mortality in otherwise manageable cases is generally low with proper treatment.

Vaccination:

Vaccination is the cornerstone of prevention for the viral components of the URI complex.

• ·Core vaccines: Modified-live or killed vaccines targeting FHV-1 and FCV are classified as core vaccines by major feline vaccination guidelines (WSAVA, AAFP). These are typically delivered as combination vaccines (e.g., FVRCP: Feline Viral Rhinotracheitis, Calicivirus, Panleukopenia).
• ·Primary series: Kittens receive a series starting at 6–8 weeks of age, with boosters every 3–4 weeks until 16 weeks of age. Adult cats with unknown vaccination history receive 2 doses 3–4 weeks apart.
• ·Booster schedule: A booster at 1 year post-primary series, then every 3 years for low-risk cats; annual boosters recommended for high-risk cats (multi-cat households, catteries, outdoor access).
• ·Intranasal vaccines: Intranasal modified-live FHV-1/FCV (and sometimes Bordetella) vaccines stimulate local mucosal immunity at the site of infection and can provide more rapid protection (onset within days). They are particularly valuable in shelter settings for rapid population protection.
• ·FCV strain coverage: Because FCV is highly variable, current vaccines incorporate multiple strains (including strains such as FCV 255 and strain F9) to maximize cross-protection; no vaccine provides 100% protection against all circulating strains.
• ·Important caveat: Vaccination does not prevent infection or latency but significantly reduces clinical severity and viral shedding. Vaccinated cats can still be infected and shed virus, though typically with milder signs.

Chlamydia felis vaccine: Available in some regions as part of combination products; recommended for high-risk catteries. Non-core vaccine; does not prevent infection but reduces clinical severity.

Bordetella bronchiseptica vaccine: Intranasal vaccine available; recommended for cats in high-density housing or with known exposure risk.

Environmental and Husbandry Measures:

• ·Isolation of new or sick cats: Strict quarantine of new arrivals for a minimum of 2 weeks (ideally 4 weeks) before introduction to existing populations; immediate isolation of cats showing clinical signs.
• ·Stress reduction: Minimizing psychosocial stress (e.g., overcrowding, inter-cat aggression, sudden environmental changes) reduces the risk of FHV-1 reactivation and immune suppression.
• ·Hygiene and disinfection: Regular cleaning and disinfection of food bowls, litter boxes, bedding, and cages. FHV-1 is enveloped and susceptible to most disinfectants; FCV (non-enveloped) is more environmentally resistant and requires sodium hypochlorite (bleach at 1:32 dilution), accelerated hydrogen peroxide, or potassium peroxymonosulfate-based products.
• ·Density management: Limiting the number of cats per airspace; adequate ventilation reduces aerosol transmission. In shelters, "all-in, all-out" housing practices for groups reduce cross-infection.
• ·Nutritional management: Ensuring optimal nutrition supports immune competence.
• ·Testing and screening: In breeding catteries, testing breeding cats for FHV-1 and FCV carrier status (via PCR) can help inform management decisions.
• ·Hand hygiene: Thorough hand washing between handling individual cats, particularly in multi-cat facilities, is essential to prevent fomite transmission.